Minireviews
Copyright ©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Table 3 Results of the REFLECT trial[34]
Lenvatinib (n = 478)Sorafenib (n = 476)HR, P-value
OS (M, 95% CI)13.6 (12.1-14.9)12.3 (10.4-13.9)HR 0.92 (0.79-1.06)
PFS (M, 95% CI)7.3 (5.6-7.5)3.6 (3.6-3.7)HR 0.64 (0.55-0.75) P < 0.0001
TTP (M, 95% CI)7.4 (7.2-9.1)3.7 (3.6-3.9)HR 0.60 (0.51-0.71) P < 0.0001
Objective response (independent review, mRECIST)
CR10 (2%)4 (1%)
PR184 (38%)55 (12%)
SD159 (33%)219 (46%)
PD79 (17%)152 (32%)
ORR194 (40.6%)59 (12.4%)P < 0.0001
DCR353 (73.8%)278 (58.4%)P < 0.0001